Nuvation Bio receives FDA clearance for NUV-1511 IND in advanced solid tumors
In a significant stride for cancer treatment, Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company dedicated to addressing unmet needs in oncology, announced the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application for NUV-1511. This marks a pivotal moment for the company as NUV-1511 is the first clinical candidate […]